ImmunityBio is a clinical-stage and commercial biotech focused on immunotherapy, including cytokine-based and cell-based approaches to cancer and infectious disease. Its lead commercial product Anktiva (nogapendekin alfa inbakicept) is used with BCG for certain forms of non-muscle invasive bladder cancer. The pipeline centers on activating the innate and adaptive immune system rather than classic chemotherapy alone.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 16.5 | — | -129.7 | — |
| Q2 2025 | 26.4 | — | -92.6 | — |
| Q3 2025 | 32.1 | — | -67.3 | — |
| Q4 2025 | 38.3 | — | -61.9 | — |
| Q1 2026 | 44.2 | 167.6% | -632.8 | — |
| Q2 2026 | 51.2 | 93.9% | -230.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Wintrust Financial Corporation (WTFC), Quantinuum Inc. (QNT), Littelfuse, Inc. (LFUS), Old National Bancorp (ONB), Advanced Energy Industries, Inc. (AEIS), Galaxy Digital (GLXY)